An Open-Label Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304

Status: Enrolling by Invitation

Description

This is a multi-center, open-label, study to evaluate the safety and efficacy of ublituximab (TG-1101) in combination with TGR-1202 for patients who have progressed on treatment arms previously enrolled in Protocol UTX-TGR-304

Eligibility Criteria

Inclusion Criteria

  • Prior treatment in clinical trial UTX-TGR-304
  • Eastern Cooperative Oncology Group (ECOG) score of 0 to 2

Exclusion Criteria

  • Patients refractory to ublituximab + TGR-1202
  • Transformation of CLL to aggressive Non-Hodgkin's Lymphoma (NHL) (Richter's transformation)

Locations & Contacts

California

Duarte
City of Hope Comprehensive Cancer Center
Status: Active
Contact: Tanya Siddiqi
Phone: 800-826-4673
Email: becomingapatient@coh.org

Connecticut

New Haven
Yale University
Status: Active
Contact: Laura Leary
Phone: 203-800-1969
Email: laura.leary@yale.edu

Kansas

Kansas City
University of Kansas Cancer Center
Status: Active
Name Not Available
Overland Park
University of Kansas Cancer Center-Overland Park
Status: Active
Name Not Available
Westwood
University of Kansas Hospital-Westwood Cancer Center
Status: Active
Name Not Available

Missouri

Kansas City
The University of Kansas Cancer Center-North
Status: Active
Name Not Available
The University of Kansas Cancer Center-South
Status: Active
Name Not Available

New Hampshire

Lebanon
Dartmouth Hitchcock Medical Center
Status: Active
Contact: Frederick Lansigan
Phone: 800-639-6918
Email: cancer.research.nurse@dartmouth.edu

North Carolina

Durham
Duke University Medical Center
Status: Active
Contact: Danielle M Brander
Phone: 888-275-3853
Email: danielle.brander@dm.duke.edu

Pennsylvania

Philadelphia
University of Pennsylvania / Abramson Cancer Center
Status: Active
Name Not Available

Virginia

Charlottesville
University of Virginia Cancer Center
Status: Active
Name Not Available

Washington

Seattle
Fred Hutch / University of Washington Cancer Consortium
Status: Active
Name Not Available

Trial Phase & Type

Trial Phase

Phase II

Trial Type

Treatment

Lead Organization

Lead Organization
TG Therapeutics Inc

Trial IDs

Primary ID UTX-TGR-204
Secondary IDs NCI-2016-01255
Clinicaltrials.gov ID NCT02656303